Meta-analysis shows fluoroquinolone antibiotics improve clinical efficacy and cure rates in pelvic inflammatory disease, suggesting better outcomes than alternatives.
Key Points
Pelvic inflammatory disease treatment with fluoroquinolone antibiotics led to a statistically significant improvement in clinical efficacy.
The cure rate recorded for the treatment group was 66.43%, surpassing the control group's rate of 62.42%.
Randomized controlled trials assessed the impact of fluoroquinolone antibiotics, highlighting their effects on inflammatory markers, including WBC and CRP levels.
Further large-scale studies are warranted to evaluate the long-term safety of fluoroquinolone use in pelvic inflammatory disease treatment.